Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Elizabete Pumpure; Eva Dručka; Dana Kigitoviča; Raimundas Meškauskas; Sergejs Isajevs; Ineta Nemiro; Agnija Rasa; Evija Olmane; Tatjana Zablocka; Pēteris Alberts; Simona Doniņa

doi:10.1002/ccr3.2928

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir^® therapy: A case report

Clin Case Rep. 2020 May 22;8(8):1538-1543. doi: 10.1002/ccr3.2928. eCollection 2020 Aug.

Authors

Elizabete Pumpure^{1

2}, Eva Dručka³, Dana Kigitoviča³, Raimundas Meškauskas⁴, Sergejs Isajevs^{5

6}, Ineta Nemiro⁷, Agnija Rasa⁸, Evija Olmane⁹, Tatjana Zablocka^{5

6}, Pēteris Alberts⁸, Simona Doniņa^{10

11}

Affiliations

¹ Department of Obstetrics and Gynaecology Riga Stradiņš University Riga Latvia.
² Riga Maternity Hospital Riga Latvia.
³ Department of Internal Diseases Riga Stradiņš University Riga Latvia.
⁴ National Center of Pathology Affiliate of Vilnius University Hospital Santaros Klinikos Vilnius Lithuania.
⁵ Centre of Pathology Riga Eastern Clinical University Hospital Riga Latvia.
⁶ Department of Pathology Faculty of Medicine University of Latvia Riga Latvia.
⁷ Department of Diagnostic Radiology Oncology Centre of Latvia Riga Latvia.
⁸ R&D, Rigvir Riga Latvia.
⁹ Department of Radiology Pauls Stradiņš Clinical University Hospital Riga Latvia.
¹⁰ Oncology Centre of Latvia Riga East University Hospital Riga Latvia.
¹¹ Institute of Microbiology and Virology Riga Stradiņš University Riga Latvia.

Abstract

Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir^® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression-free survival are good.

Keywords: ECHO‐7 virus; Rigvir; melanoma; oncology; oncolytic virus; uterine cervix.

Publication types

Case Reports